XNAS · Healthcare · Biotechnology
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | Q1 2026 | -1.08 | -1.34 | -24.07% | $0 | ❌ Miss | +0.00% | -0.03% | -5.26% |
| 2026-03-26 | Q4 2025 | -0.92 | -2.47 | -168.48% | $0 | ❌ Miss | -3.53% | +10.09% | +54.76% |
| 2025-12-04 |
| Q3 2025 |
| -1.36 |
| -37.18 |
| -2633.82% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
Showing last 3 quarters.